|
CA2947603A1
|
|
Demonstrable efficacy across or within patient populations
|
|
US2015313819A1
|
|
Methods to treat, prevent, and improve skin conditions
|
|
AU2013204319A1
|
|
Peptide nanoparticles and uses therefor
|
|
WO2012103038A2
|
|
Nanoparticle compositions, formulations thereof, and uses therefor
|
|
WO2012103036A1
|
|
Compositions of empty nanoparticles and their use for treating dermatological conditions
|
|
KR20140003572A
|
|
Nanoparticle compositions
|
|
EP2667945A1
|
|
Oil compositions
|
|
WO2012103040A1
|
|
Paraben compositions
|
|
AU2009261995A1
|
|
Dermal delivery
|
|
EP2162117A2
|
|
Nucleic acid nanoparticles and uses therefor
|
|
AU2007353340A1
|
|
Peptide nanoparticles and uses therefor
|
|
BRPI0719756A2
|
|
Amphiphilic Nanoparticles
|
|
EP2015773A2
|
|
Assessment of the effects of topical administration of chemodenervating pharmaceuticals
|
